1464-5491/asset/dme_left.gif?v=1&s=709479eec257345efd8869220bba03cf955b1626)
1464-5491/asset/dme_right.gif?v=1&s=5ab89a93bea1edfb131e4785d6bd3738828d7357)
Ergotamine use in severe diabetic autonomic neuropathy
Article first published online: 20 APR 2006
DOI: 10.1111/j.1464-5491.2006.01844.x
Additional Information
How to Cite
Toh, V., Duncan, E., Lewis, N., Fichter, L. and Matthews, D. R. (2006), Ergotamine use in severe diabetic autonomic neuropathy. Diabetic Medicine, 23: 574–576. doi: 10.1111/j.1464-5491.2006.01844.x
Publication History
- Issue published online: 20 APR 2006
- Article first published online: 20 APR 2006
- Accepted 19 October 2005
- Abstract
- Article
- References
- Cited By
Keywords:
- postural hypotension;
- diabetes;
- autonomic neuropathy;
- fludrocortisone;
- midodrine;
- octreotide;
- erythropoieten;
- ergotamine;
- caffeine
Abstract
Background Symptomatic postural hypotension in diabetes is uncommon. When it does occur, it can prove debilitating and difficult to treat. We report here the therapeutic challenges encountered in managing a patient with severe postural hypotension secondary to diabetes-related autonomic neuropathy.
Case report A 69-year-old gentleman with a 23-year history of Type 1 diabetes mellitus and multiple microvascular complications was admitted with symptoms of severe postural hypotension. Cardiovascular autonomic testing confirmed the presence of severe autonomic neuropathy. He failed to respond to non-pharmacological measures, fludrocortisone, midodrine, octreotide, erythropoietin and increased caffeine intake. Eventually he was commenced on half a Cafergot suppository (giving him a dose of ergotamine 1 mg and caffeine 50 mg) which resulted in dramatic clinical improvement.
Conclusion Ergotamine may be considered in refractory cases of postural hypotension.